Major interaction on record — check this product against your medications before combining. Based on 7 of 9 ingredients. Check your meds →
Dietary supplement

Stomach Ache Ingredients & Drug Interactions

by BIOVEA Homeopathics

Stomach Ache label
See full label image
Liquid Category: Other Combinations
Most serious interaction: Major
Clinical methodology reviewed by · Updated Sep 9, 2026 · Label data from the NIH DSLD
What is this page for?

First and foremost: checking Stomach Ache against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.

Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy

The interaction bottom line Most serious interaction: Major

Stomach Ache is a dietary supplement by BIOVEA Homeopathics with 9 active ingredients. Its ingredients are commonly taken for hair, skin, and nail health, bone health and osteoporosis, joint and connective tissue support.Based on those ingredients, 2,106 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are Carbo Veg, Cinchona, Calc sulph. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

Jump to a section

Check Your Meds Against Stomach Ache by BIOVEA Homeopathics

Ask about any prescription or over-the-counter medication and we check it for interactions with Stomach Ache by BIOVEA Homeopathics — and tell you which ingredient is responsible.

Pharmacist-reviewed data Checks every ingredient Answer in seconds
Prefer a human? Send your question to our licensed pharmacists — free, answered by email within 24 hours.

HelloPharmacist Scorecard of Stomach Ache by BIOVEA Homeopathics

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

Generated from HelloPharmacist’s pharmacist-curated databases and editorial rules · Last generated Jul 11, 2026

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 9 active ingredients.

This product contains 9 ingredients. The active ones are Silicea (a form of silicon), Pyrogenium, Arsenicum alb (arsenic), Calc sulph (calcium sulfate), Carbo An, Carbo Veg (activated charcoal), Cinchona (a plant extract containing quinidine and quinine), Nux vom (nux vomica, which contains strychnine), and Ornithogalum (star of Bethlehem, a plant containing cardiac glycosides — compounds that affect heart function).

The inactive ingredients are organic alcohol and purified water.

Does it work?

Strong evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Strong

Clinical evidence supports at least one of this product's ingredients for its stated purpose.

Why this rating?
  • The label markets this product for: temporary relief of stomach distress symptoms.
  • We looked for evidence on: Dyspepsia, Flatulence, Hangover, indigestion, stomach cramps, gastric upset.
  • The strongest evidence on file: Calcium is rated "Effective" for Dyspepsia (Natural Medicines).
  • Also on file: Activated Charcoal is rated "Insufficient Reliable Evidence To Rate" for Dyspepsia, Flatulence, Hangover.

The evidence on these ingredients is very limited in our data. Silicea is possibly effective for osteoporosis but has insufficient evidence for hair loss or dental problems.

Calc sulph is effective for kidney failure, heartburn, low blood calcium, and high potassium levels, and likely effective for weak bones. For most other ingredients — Cinchona, Carbo Veg, Ornithogalum, and Nux vom — the data shows insufficient evidence to rate their effectiveness for any condition.

Arsenicum alb is effective for a specific type of leukemia but has insufficient evidence for other uses. We hold no effectiveness data for Pyrogenium or Carbo An.

The evidence, ingredient by ingredient Silicon Arsenic Calcium Activated Charcoal Cinchona Nux Vomica Star Of Bethlehem

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 7 of the 7 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 7 of 7.
  • General safety write-ups exist for 7 of 7.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Several ingredients in this product carry real safety concerns. Arsenicum alb is a known poison and carcinogen — the facts advise against using it as a supplement, and it should not be taken during pregnancy or while breastfeeding.

Nux vom contains strychnine, a highly toxic poison; even small amounts can trigger muscle spasms and seizures within 15 minutes, and concentrated forms can be fatal. It should be avoided during pregnancy and breastfeeding.

Cinchona contains quinine, which can cause serious blood disorders, heart rhythm problems, and fatal cardiac arrhythmias; it should be avoided in pregnancy and while breastfeeding. Ornithogalum (star of Bethlehem) contains cardiac glycosides that can cause dangerous heart rhythms and death; safety in pregnancy and breastfeeding is not established.

Silicea is generally well tolerated from food and most supplements, but long-term high-dose safety is not well studied. Calc sulph is generally safe at recommended doses.

Carbo Veg is generally well tolerated for short-term use but can cause constipation and reduce absorption of other substances; use in pregnancy is not well studied. Nux vom and Cinchona should not be used at all during pregnancy or breastfeeding.

Side effects, ingredient by ingredient Silicon Arsenic Calcium Activated Charcoal Cinchona Nux Vomica Star Of Bethlehem

Meds to double-check

Major interaction found
Known Interaction Concern · database check
Major identified

At least one ingredient has a documented Major-severity interaction. Check your medications for a personalized result.

Why this rating?
  • 5 of the 7 matched ingredients can interact with medications — Activated Charcoal, Cinchona, Calcium, Star Of Bethlehem, Arsenic.
  • The most serious interaction on file is rated Major.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; heart-rhythm medications; lithium.
  • For scale: 2,107 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Check with your pharmacist before taking this product if you use heart rhythm drugs (especially QT-prolonging drugs), blood thinners or antiplatelet drugs, HIV medications (dolutegravir, elvitegravir, raltegravir), the antibiotic ceftriaxone, thyroid hormone (levothyroxine), heart drugs like sotalol or diltiazem, oral contraceptives, corticosteroids, diuretics, stimulant laxatives, certain antibiotics (macrolides or tetracyclines), digoxin, seizure medications (phenobarbital, carbamazepine), or antacids. No interactions are documented for Silicea or Nux vom in our data, and we could not check Pyrogenium or Carbo An.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with clinical evidence supporting its stated purpose. Major medication interactions have been identified, and safety information is well characterized.

This product contains ingredients with serious safety and interaction risks, including a known poison (arsenic) and a highly toxic substance (strychnine). If you take any prescription medications, especially heart drugs, blood thinners, thyroid medication, HIV drugs, or antibiotics, do not take this product without checking first with your pharmacist or doctor.

Pregnant women and those breastfeeding should not use it.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 7 of 9 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated May 22, 2021.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Stomach Ache, straight from the product label.

Brand BIOVEA Homeopathics
Barcode (UPC) 818423024943
Net contents 1 fl. Oz.; 30 mL
Market status On market
Date entered into DSLD May 22, 2021
DSLD ID 249153
Product type Other Combinations
Supplement form Liquid
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Organic
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Stomach Ache by BIOVEA Homeopathics, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
2 Spray(s)
Maximum serving Sizes:
2 Spray(s)
UPC/BARCODE
818423024943
IngredientAmount% DV
Silicea0 NP--
Pyrogenium0 NP--
Arsenicum alb0 NP--
Calc sulph0 NP--
Carbo An0 NP--
Carbo Veg0 NP--
Cinchona0 NP--
Nux vom0 NP--
Ornithogalum0 NP--

Other ingredients: organic Alcohol, purified Water

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formulation

Indications: Fast-acting homeopathic oral spray for the temporary relief of nausea, indigestion, stomach cramps and flatulence associated with stomach distress.

Homeopathic

Digestion

Suggested/Recommended/Usage/Directions

Directions: Adults & children over 12. Spray twice under the tongue 3 times per day. For severe symptoms, dosage may be taken up to six times the first day. Children 12 & under. Consult a doctor prior to use.

Precautions

Children 12 & under. Consult a doctor prior to use.

Warnings: If symptoms persist, consult a doctor.

If pregnant or breast feeding, ask a doctor before use.

Keep out of reach of children.

In case of accidental overdose, get medical help or call a Poison Control Center right away. Do not use if tamper evident seal is broken or missing.

General

NDC# 69607-0010-1

Formula

20% organic alcohol

FDA Disclaimer Statement

These statements are based upon traditional homeopathic practice. They have not been reviewed by the Food and Drug Administration.

Is this label outdated? Report a formula or label change and our pharmacy team will review it.

See for yourself

Stomach Ache by BIOVEA Homeopathics label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

Stomach Ache label

Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.

View the full label (PDF)
What’s inside

The Ingredients in Stomach Ache by BIOVEA Homeopathics

These are the 9 active ingredients this product is made of. Select any to open its full monograph.

Serving size2 Spray(s) Dosage formLiquid Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Silicea

No known
interactions
0 NP per serving

Silicon is a trace mineral found in the body and in foods like oats, barley, and certain fruits and vegetables, and it is popular in supplements for h...

Silicea monograph & interactions

Pyrogenium

0 NP per serving

Arsenicum alb

Interacts with
161 drugs
0 NP per serving

Arsenic is a naturally occurring element that is toxic in its inorganic form, and it is not a supplement you should take to improve your health. While...

Arsenicum alb monograph & interactions

Calc sulph

Interacts with
168 drugs
0 NP per serving

Calcium is an essential mineral your body needs for strong bones, nerve signaling, and muscle function, and supplements can help fill gaps when diet f...

Calc sulph monograph & interactions

Carbo An

0 NP per serving

Carbo Veg

Interacts with
2,027 drugs
0 NP per serving

Activated charcoal is a highly porous form of carbon that can bind certain substances in the gut, and it is used in hospitals to treat some poisonings...

Carbo Veg monograph & interactions

Cinchona

Interacts with
492 drugs
0 NP per serving

Cinchona bark is the natural source of quinine and has been used for centuries to treat malaria and fever, but the bark itself is not standardized and...

Cinchona monograph & interactions

Nux vom

No known
interactions
0 NP per serving

Nux vomica comes from a tree seed that contains strychnine, a powerful and potentially deadly poison. It is mostly sold today in extremely diluted hom...

Nux vom monograph & interactions

Ornithogalum

Interacts with
156 drugs
0 NP per serving

Star of Bethlehem is a small flowering plant best known as one of the ingredients in Bach flower remedies, where it is used for emotional shock and gr...

Ornithogalum monograph & interactions

Other (inactive) ingredients: Organic Alcohol, Purified Water. These complete the product’s ingredient list but are not active constituents.

Interaction report

Stomach Ache by BIOVEA Homeopathics Drug Interactions

Want to check YOUR meds against Stomach Ache?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

 Go to the checker
2,106Drugs
2,053 Major 53 Moderate

Ingredients driving the most interactions

Carbo Veg 2,027
Cinchona 492
Calc sulph 168
Arsenicum alb 161
Ornithogalum 156

Individual Drug Interactions

The ingredients in Stomach Ache interact with 2,106 drugs. Click any drug to see the details.

5 of the 9 ingredients in Stomach Ache interact with drugs. Each result below shows which ingredient is responsible. Carbo Veg Cinchona Calc sulph Arsenicum alb Ornithogalum

Each ingredient & the kinds of drugs it affects

For each ingredient in Stomach Ache with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Carbo Veg3 drug types · 2,027 drugs

Oral Drugs

Activated charcoal reduces systemic exposure to many drugs, including those that undergo enterohepatic recirculation, regardless of the route of administration.
Activated charcoal adsorbs various drugs and may reduce their absorption and/or half-life. Examples of affected drugs include acetaminophen, aminophylline, amiodarone, atenolol, carbamazepine, dapsone, digoxin, disopyramide, fluoxetine, indomethacin, moxifloxacin, nadolol, phenytoin, phenobarbital, piroxicam, quinine, sotalol, theophylline, tricyclic antidepressants, valproate, and verapamil. Avoid co-administration, except after drug overdose.

Likelihood Probable Evidence B
Alcohol (Ethanol)

The binding action of activated charcoal may be reduced by alcohol.
Alcohol may lower the adsorptive capacity of activated charcoal.

Likelihood Probable Evidence D
Contraceptive Drugs

Activated charcoal may reduce the clinical effects of oral contraceptives.
Activated charcoal, taken in a dose of 5 grams four times daily for 3 days, may bind to, and reduce the absorption of, oral contraceptives, thereby limiting their effectiveness and increasing the risk of contraceptive failure. However, some clinical research shows that the risk for this interaction is minimal when activated charcoal is taken either 3 hours after or at least 12 hours before oral contraceptives.

Likelihood Possible Evidence B
Carbo Veg full monograph & interactions

Cinchona11 drug types · 492 drugs

Quinidine

Theoretically, taking cinchona might increase plasma levels and adverse effects of quinidine.
Cinchona contains quinidine.

Likelihood Probable Evidence D
Quinine

Theoretically, taking cinchona might increase plasma levels and adverse effects of quinine.
Cinchona contains quinine.

Likelihood Probable Evidence D
Antacids

Theoretically, taking cinchona might decrease the effectiveness of antacids. Theoretically, taking antacids might also increase the risk of adverse effects from cinchona.
Some research shows that taking cinchona lowers stomach acid pH. In addition, some research shows that taking antacids might increase urinary pH. Theoretically, this may increase the amount of quinidine, a constituent of cinchona, reabsorbed in the renal tubules and increase the risk of quinidine toxicity.

Likelihood Possible Evidence D
Anticoagulant/Antiplatelet Drugs

Theoretically, taking cinchona might increase the drug effects and risk of bleeding with anticoagulant and antiplatelet drugs.
In vitro evidence shows that the alkaloids quinine, quinidine, and cinchonine, constituents of cinchona, inhibit platelet aggregation.

Likelihood Possible Evidence D
Carbamazepine (Tegretol)

Theoretically, taking cinchona might increase the adverse effects of carbamazepine.
Clinical research shows that taking quinine, a constituent of cinchona, increases the peak plasma concentration and area under the curve of carbamazepine.

Likelihood Probable Evidence B
Cytochrome P450 2D6 (Cyp2D6) Substrates

Theoretically, taking cinchona might inhibit cytochrome P450 2D6 (CYP2D6) and increase levels of drugs metabolized by this enzyme.
Quinidine, a constituent of cinchona, inhibits CYP2D6-mediated metabolism in humans.

Likelihood Possible Evidence D
Digoxin (Lanoxin)

Theoretically, taking cinchona might increase serum levels of digoxin.
Quinine and quinidine, which are constituents of cinchona, decrease clearance of digoxin and increase serum digoxin levels in humans.

Likelihood Possible Evidence D
Phenobarbital (Luminal)

Theoretically, taking cinchona might increase the adverse effects of phenobarbital.
Clinical research shows that taking quinine, a constituent of cinchona, increases the peak plasma concentration and area under the curve of phenobarbital.

Likelihood Probable Evidence D
Qt Interval-Prolonging Drugs

Theoretically, taking cinchona with other QT interval-prolonging drugs might cause an additive effect and increase the risk of ventricular arrhythmias.
Quinidine and quinine, which are constituents of cinchona, prolong the QT interval.

Likelihood Possible Evidence D
H2-Blockers

Theoretically, taking cinchona might decrease the effectiveness of H2-blockers.
Some research shows that taking cinchona lowers stomach acid pH.

Likelihood Possible Evidence D
Proton Pump Inhibitors (Ppis)

Theoretically, taking cinchona might decrease the effectiveness of PPIs.
Some research shows that taking cinchona lowers stomach acid pH.

Likelihood Possible Evidence D
Cinchona full monograph & interactions

Calc sulph18 drug types · 168 drugs

Ceftriaxone (Rocephin)

Co-administration of intravenous calcium and ceftriaxone can result in precipitation of a ceftriaxone-calcium salt in the lungs and kidneys.
Avoid administering intravenous calcium in any form, such as parenteral nutrition or Lactated Ringers, within 48 hours of intravenous ceftriaxone. Case reports in neonates show that administering intravenous ceftriaxone and calcium can result in precipitation of a ceftriaxone-calcium salt in the lungs and kidneys. In several cases, neonates have died as a result of this interaction. So far there are no reports in adults; however, there is still concern that this interaction might occur in adults.

Likelihood Probable Evidence D
Dolutegravir (Tivicay)

Calcium seems to reduce levels of dolutegravir.
Advise patients to take dolutegravir either 2 hours before or 6 hours after taking calcium supplements. Pharmacokinetic research suggests that taking calcium carbonate 1200 mg concomitantly with dolutegravir 50 mg reduces plasma levels of dolutegravir by almost 40%. Calcium appears to decrease levels of dolutegravir through chelation.

Likelihood Probable Evidence B
Elvitegravir (Vitekta)

Calcium seems to reduce levels of elvitegravir.
Advise patients to take elvitegravir either 2 hours before or 2 hours after taking calcium supplements. Pharmacokinetic research suggests that taking calcium along with elvitegravir can reduce blood levels of elvitegravir through chelation.

Likelihood Probable Evidence B
Aluminum

Calcium citrate might increase aluminum absorption and toxicity. Other types of calcium do not increase aluminum absorption.
Calcium citrate can increase the absorption of aluminum when taken with aluminum hydroxide. The increase in aluminum levels may become toxic, particularly in individuals with kidney disease. However, the effect of calcium citrate on aluminum absorption is due to the citrate anion rather than calcium cation. Calcium acetate does not appear to increase aluminum absorption.

Likelihood Possible Evidence B
Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy)

Calcium might decrease levels of bictegravir/emtricitabine/tenofovir alafenamide by reducing its absorption when taken in a fasting state.
Advise patients that bictegravir/emtricitabine/tenofovir alafenamide and calcium can be taken together if taken with food. However, if taken on an empty stomach, bictegravir/emtricitabine/tenofovir alafenamide should not be taken with, or 2 hours after, calcium containing products.

Likelihood Probable Evidence D
Bisphosphonates

Calcium reduces the absorption of bisphosphonates.
Advise patients to take bisphosphonates at least 30 minutes before calcium, but preferably at a different time of day. Calcium supplements decrease absorption of bisphosphonates.

Likelihood Probable Evidence C
Calcipotriene (Dovonex)

Taking calcipotriene with calcium might increase the risk for hypercalcemia.
Calcipotriene is a vitamin D analog used topically for psoriasis. It can be absorbed in sufficient amounts to cause systemic effects, including hypercalcemia. Theoretically, combining calcipotriene with calcium supplements might increase the risk of hypercalcemia.

Likelihood Possible Evidence B
Digoxin (Lanoxin)

Using intravenous calcium with digoxin might increase the risk of fatal cardiac arrhythmias.
Hypercalcemia increases the risk of fatal cardiac arrhythmias with digoxin. However, one retrospective analysis of clinical data suggests that intravenous calcium does not increase the risk of dysrhythmias or mortality in patients receiving digoxin.

Likelihood Possible Evidence B
Diltiazem (Cardizem, Others)

Theoretically, calcium may reduce the therapeutic effects of diltiazem.
Hypercalcemia can reduce the effectiveness of verapamil in atrial fibrillation. Theoretically, calcium might increase this risk of hypercalcemia and reduce the effectiveness of diltiazem.

Likelihood Probable Evidence D
Levothyroxine (Synthroid, Others)

Calcium seems to reduce the absorption and effectiveness of levothyroxine.
Advise patients to take levothyroxine and calcium supplements at least 4 hours apart. Calcium reduces levothyroxine absorption, probably by forming insoluble complexes. Calcium carbonate supplements reduce effectiveness of levothyroxine in patients with hypothyroidism.

Likelihood Probable Evidence B
Lithium

Theoretically, concomitant use of calcium and lithium may increase this risk of hypercalcemia.
Clinical research suggests that long-term use of lithium may cause hypercalcemia in 10% to 60% of patients. Theoretically, concomitant use of lithium and calcium supplements may further increase this risk.

Likelihood Possible Evidence B
Quinolone Antibiotics

Calcium seems to reduce the absorption of quinolone antibiotics.
Advise patients to take oral quinolones at least 2 hours before or 4-6 hours after calcium supplements or calcium-fortified foods. Taking calcium at the same time as oral quinolones can reduce quinolone absorption. Calcium binds to quinolones in the gut.

Likelihood Probable Evidence B
Raltegravir (Isentress)

Calcium may reduce levels of raltegravir.
Pharmacokinetic research shows that taking a single dose of calcium carbonate 3000 mg along with raltegravir 400 mg twice daily modestly decreases the mean area under the curve of raltegravir, but the decrease does not necessitate a dose adjustment of raltegravir. However, a case of elevated HIV-1 RNA levels and documented resistance to raltegravir has been reported for a patient taking calcium carbonate 1 gram three times daily plus vitamin D3 (cholecalciferol) 400 IU three times daily in combination with raltegravir 400 mg twice daily for 11 months. It is thought that calcium reduced raltegravir levels by chelation, leading to treatment failure.

Likelihood Possible Evidence B
Sotalol (Betapace)

Calcium seems to reduce the absorption of sotalol.
Advise patients to separate doses by at least 2 hours before or 4-6 hours after calcium. Calcium appears to reduce the absorption of sotalol, probably by forming insoluble complexes.

Likelihood Possible Evidence B
Tetracycline Antibiotics

Calcium seems to reduce the absorption of tetracycline antibiotics.
Advise patients to take oral tetracyclines at least 2 hours before, or 4-6 hours after calcium supplements. Taking calcium at the same time as oral tetracyclines can reduce tetracycline absorption. Calcium binds to tetracyclines in the gut.

Likelihood Probable Evidence C
Thiazide Diuretics

Taking calcium along with thiazides might increase the risk of hypercalcemia and renal failure.
Thiazides reduce calcium excretion by the kidneys. Using thiazides along with moderately large amounts of calcium carbonate increases the risk of milk-alkali syndrome (hypercalcemia, metabolic alkalosis, renal failure). Patients may need to have their serum calcium levels and/or parathyroid function monitored regularly.

Likelihood Probable Evidence C
Verapamil (Calan, Others)

Theoretically, calcium may reduce the therapeutic effects of verapamil.
Hypercalcemia can reduce the effectiveness of verapamil in atrial fibrillation. Theoretically, use of calcium supplements may increase this risk of hypercalcemia and reduce the effectiveness of verapamil.

Likelihood Probable Evidence D
Calcium Channel Blockers

Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Intravenous calcium is used to decrease the effects of calcium channel blockers in the management of overdose. Intravenous calcium gluconate has been used before intravenous verapamil (Isoptin) to prevent or reduce the hypotensive effects without affecting the antiarrhythmic effects. But there is no evidence that dietary or supplemental calcium when taken orally interacts with calcium channel blockers.

Likelihood Unlikely Evidence D
Calc sulph full monograph & interactions

Arsenicum alb1 drug type · 161 drugs

Qt Interval-Prolonging Drugs

Arsenic trioxide can prolong the QT interval.
Up to 40% of patients treated with prescription arsenic trioxide have a prolonged QT interval on their electrocardiogram (ECG). Theoretically, non-prescription arsenic could have an additive effect when combined with drugs that prolong the QT interval.

Likelihood Probable Evidence B
Arsenicum alb full monograph & interactions

Ornithogalum7 drug types · 156 drugs

Corticosteroids

Theoretically, taking star of Bethlehem with prolonged corticosteroid therapy might increase the risk of toxicity.
Star of Bethlehem contains cardiac glycosides. Concomitant use of corticosteroids with star of Bethlehem can increase the therapeutic and adverse effects of long-term corticosteroid use due to potassium depletion and electrolyte imbalance.

Likelihood Possible Evidence D
Digoxin (Lanoxin)

Theoretically, taking star of Bethlehem in combination with digoxin might have additive effects and increase the risk of toxicity.
Star of Bethlehem contains cardiac glycosides with effects similar to digoxin.

Likelihood Possible Evidence D
Diuretic Drugs

Theoretically, taking diuretics with star of Bethlehem might increase the risk of toxicity.
Star of Bethlehem contains cardiac glycosides. Theoretically, concomitant use of potassium-depleting diuretics and star of Bethlehem can increase the risk of cardiac glycoside toxicity due to potassium depletion.

Likelihood Possible Evidence D
Macrolide Antibiotics

Theoretically, taking macrolide antibiotics with star of Bethlehem might increase the risk of cardiac glycoside toxicity.
Star of Bethlehem contains cardiac glycosides. Macrolide antibiotics appear to increase the gastrointestinal absorption of oral digoxin. Theoretically, concomitant use of macrolide antibiotics might increase the absorption of the cardiac glycosides found in star of Bethlehem and increase the risk of adverse effects.

Likelihood Possible Evidence D
Quinine

Theoretically, taking quinine with star of Bethlehem might increase the risk of cardiac glycoside toxicity.
Star of Bethlehem contains cardiac glycosides. Quinine may reduce the clearance of oral digoxin. Theoretically, concomitant use of quinine might reduce the clearance of cardiac glycosides found in star of Bethlehem and increase the risk of adverse effects.

Likelihood Possible Evidence D
Stimulant Laxatives

Theoretically, excessive use of stimulant laxatives with star of Bethlehem might increase the risk of toxicity.
Star of Bethlehem contains cardiac glycosides. Excessive use of stimulant laxatives can cause diarrhea, resulting in potassium depletion. This might increase the risk of cardiac glycoside toxicity.

Likelihood Possible Evidence D
Tetracycline Antibiotics

Theoretically, taking tetracycline antibiotics with star of Bethlehem might increase the risk of cardiac glycoside toxicity.
Star of Bethlehem contains cardiac glycosides similar to digitalis. Tetracycline antibiotics appear to increase the gastrointestinal absorption of oral digoxin. Theoretically, concomitant use of tetracycline antibiotics might increase the absorption of the cardiac glycosides found in star of Bethlehem and increase the risk of adverse effects.

Likelihood Possible Evidence D
Ornithogalum full monograph & interactions
The maker

Brand information

Manufacturer and brand details for Stomach Ache, from the product label.

BIOVEA Homeopathics

See all BIOVEA Homeopathics products
Name
BIOVEA
Street Address
7702 E. Doubletree Ranch Rd. Suite 300, #307
City
Scottsdale
State
AZ
ZipCode
85258
Phone Number
1-800-961-4750
Web Address
www.biovea.com
Pharmacist Counseling Corner

Stomach Ache by BIOVEA Homeopathics: Common Questions

Does Stomach Ache by BIOVEA Homeopathics interact with any medications?
Yes. Based on its ingredients, Stomach Ache has a known interaction with 2,106 medications, including 2053 rated major. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Stomach Ache contains 9 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Is this safe to take if I'm pregnant?
No. Several ingredients — Arsenicum alb (arsenic), Nux vom (strychnine), Cinchona, and Ornithogalum — should be avoided during pregnancy. Silicea safety data is insufficient for pregnancy, and Carbo Veg is not well studied in pregnancy. Do not use this product if you are pregnant.
Is this safe while breastfeeding?
No. Arsenicum alb, Nux vom, Cinchona, and Ornithogalum should all be avoided while breastfeeding. Carbo Veg has little safety data for breastfeeding. Do not use this product if you are nursing.
Does activated charcoal in this product bind my medications?
Yes. Carbo Veg (activated charcoal) can bind many oral drugs and reduce how well they work — including antibiotics, anticonvulsants, and many others. It can also reduce the effectiveness of birth control pills. You'd need to take medications several hours apart from this product.
What is Nux vom and why is it in a stomach product?
Nux vom (nux vomica) is a plant seed that contains strychnine, a highly toxic poison. Even small doses can trigger muscle spasms and seizures within 15 minutes. It should not be used — homeopathic preparations may claim it's been diluted to safety, but the facts show it carries serious risk.
Why does this product contain arsenic?
Arsenicum alb is a homeopathic preparation of arsenic. Arsenic is a known poison and carcinogen. While some homeopathic products contain heavily diluted toxic substances, the facts here advise against using it as a supplement and warn against use in pregnancy and breastfeeding.
Does this product work for stomach aches?
We don't have effectiveness data for most of these ingredients for stomach complaints. The ingredients we could rate — Silicea, Calc sulph, and Carbo Veg — either lack evidence or are not established as treatments for stomach ache in our data.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Stomach Ache is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Stomach Ache label
Go deeper

The Full Monographs Behind Stomach Ache’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Herb & supplement monograph

Silicon

Silicon is a trace mineral found in the body and in foods like oats, barley, and certain fruits and vegetables, and it is popular in supplements for hair, skin, nail, and bone health. Some s...

Read the full Silicon monograph → Herb & supplement monograph

Arsenic

Interacts with 161 drugs

Arsenic is a naturally occurring element that is toxic in its inorganic form, and it is not a supplement you should take to improve your health. While arsenic trioxide is a real, doctor-pres...

Read the full Arsenic monograph → Herb & supplement monograph

Calcium

Interacts with 168 drugs

Calcium is an essential mineral your body needs for strong bones, nerve signaling, and muscle function, and supplements can help fill gaps when diet falls short. Most people do best getting...

Read the full Calcium monograph → Herb & supplement monograph

Activated Charcoal

Interacts with 2,027 drugs

Activated charcoal is a highly porous form of carbon that can bind certain substances in the gut, and it is used in hospitals to treat some poisonings and overdoses. For everyday uses like g...

Read the full Activated Charcoal monograph → Herb & supplement monograph

Cinchona

Interacts with 492 drugs

Cinchona bark is the natural source of quinine and has been used for centuries to treat malaria and fever, but the bark itself is not standardized and can be unpredictable and risky. Modern...

Read the full Cinchona monograph → Herb & supplement monograph

Nux Vomica

Nux vomica comes from a tree seed that contains strychnine, a powerful and potentially deadly poison. It is mostly sold today in extremely diluted homeopathic forms, and there is no good sci...

Read the full Nux Vomica monograph → Herb & supplement monograph

Star Of Bethlehem

Interacts with 156 drugs

Star of Bethlehem is a small flowering plant best known as one of the ingredients in Bach flower remedies, where it is used for emotional shock and grief. There is no solid scientific eviden...

Read the full Star Of Bethlehem monograph →
Sources

Sources & How We Checked

Stomach Ache's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 160 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Silicon 19 references
  1. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2002.
  2. Jugdaohsingh R, Anderson SH, Tucker KL, et al. Dietary silicon intake and absorption. Am J Clin Nutr 2002;75:887-93. PubMed
  3. Ichiyanagi O, Sasagawa I, Adachi Y, et al. Silica urolithiasis without magnesium trisilicate intake. Urol Int 1998;61:39-42. PubMed
  4. Levison DA, Crocker PR, Banim S, Wallace DM. Silica stones in the urinary bladder. Lancet 1982;1:704-5. PubMed
  5. Lee MH, Lee YH, Hsu TH, et al. Silica stone--development due to long time oral trisilicate intake. Scand J Urol Nephrol 1993;27:267-9. PubMed
  6. Cruz Guerra, N. A., Gomez Garcia, M. A., Lovaco, Castellano F., Saez Garrido, J. C., Garcia, Cuerpo E., and Escudero, Barrilero A. [Silica urolithiasis: report of a new case]. Actas Urol.Esp 2000;24(2):202-204.
  7. Merget, R., Bauer, T., Kupper, H. U., Philippou, S., Bauer, H. D., Breitstadt, R., and Bruening, T. Health hazards due to the inhalation of amorphous silica. Arch Toxicol. 2002;75(11-12):625-634. PubMed
  8. Khuder, S. A., Peshimam, A. Z., and Agraharam, S. Environmental risk factors for rheumatoid arthritis. Rev Environ Health 2002;17(4):307-315. PubMed
  9. McLaughlin, J. K., Chow, W. H., and Levy, L. S. Amorphous silica: a review of health effects from inhalation exposure with particular reference to cancer. J Toxicol.Environ Health 4-25-1997;50(6):553-566. DOI
  10. Pelucchi, C., Pira, E., Piolatto, G., Coggiola, M., Carta, P., and La, Vecchia C. Occupational silica exposure and lung cancer risk: a review of epidemiological studies 1996-2005. Ann.Oncol. 2006;17(7):1039-1050. PubMed
  11. Gillissen, A., Gessner, C., Hammerschmidt, S., Hoheisel, G., and Wirtz, H. [Health significance of inhaled particles]. Dtsch.Med Wochenschr. 3-24-2006;131(12):639-644.
  12. Hu, J. F., Qu, H., and Wang, J. Z. [Meta analysis for relationship between exposure of free silicon dioxide and lung tumor]. Zhonghua Lao.Dong.Wei Sheng Zhi.Ye.Bing.Za Zhi. 2006;24(7):415-417.
  13. Jugdaohsingh, R. Silicon and bone health. J Nutr Health Aging 2007;11(2):99-110.
  14. Lacasse, Y., Martin, S., Gagne, D., and Lakhal, L. Dose-response meta-analysis of silica and lung cancer. Cancer Causes Control 2009;20(6):925-933. PubMed
  15. McCormic, Z. D., Khuder, S. S., Aryal, B. K., Ames, A. L., and Khuder, S. A. Occupational silica exposure as a risk factor for scleroderma: a meta-analysis. Int Arch Occup.Environ Health 2010;83(7):763-769. PubMed
  16. Haddad, F. S. and Kouyoumdjian, A. Silica stones in humans. Urol.Int 1986;41(1):70-76. PubMed
  17. Tervaert, J. W., Stegeman, C. A., and Kallenberg, C. G. Silicon exposure and vasculitis. Curr Opin.Rheumatol 1998;10(1):12-17. PubMed
  18. Steenland, K. and Stayner, L. Silica, asbestos, man-made mineral fibers, and cancer. Cancer Causes Control 1997;8(3):491-503. PubMed
  19. Boqué N, Valls RM, Pedret A, Puiggrós F, Arola L, Solà R. Relative absorption of silicon from different formulations of dietary supplements: a pilot randomized, double-blind, crossover post-prandial study. Sci Rep 2021;11(1):16479. PubMed

See these in context on the Silicon monograph →

Arsenic 35 references
  1. McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
  2. Ellenhorn MJ, et al. Ellenhorn's Medical Toxicology: Diagnoses and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams & Wilkins, 1997.
  3. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2002.
  4. Uthus EO, Seaborn CD. Deliberations and evaluations of the approaches, endpoints and paradigms for dietary recommendations of the other trace elements. J Nutr 1996;126:2452s-2459s. PubMed
  5. Nielsen FH. Nutritional requirements for boron, silicon, vanadium, nickel, and arsenic: current knowledge and speculation. FASEB J 1991;5:2661-7. DOI
  6. US Department of Health and Human Services. Agency for Toxic Substances and Disease Registry. Public Health Statement: Arsenic. August 2007. Available at: www.atsdr.cdc.gov/toxprofiles/tp2-c1-b.pdf (Accessed 14 April 2008).
  7. Eckhert CD. Other trace elements. In: Shils ME, Shike M, Ross AC, et al (eds). Modern Nutrition in Health and Disease. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2006.
  8. Ratnaike RN. Acute and chronic arsenic toxicity. Postgrad Med J 2003;79:391-6. PubMed
  9. Wasserman GA, Liu X, Parvez F, et al. Water arsenic exposure and children's intellectual function in Araihazar, Bangladesh. Environ Health Perspect 2004;112:1329-33. PubMed
  10. Lamm SH, Ferdosi H, Dissen EK, Li J, Ahn J. A systematic review and meta-regression analysis of lung cancer risk and inorganic arsenic in drinking water. Int J Environ Res Public Health 2015;12(12):15498-515. PubMed
  11. Hsueh YM, Chen WJ, Lee CY, et al. Association of arsenic methylation capacity with developmental delays and health status in children: a prospective case-control trial. Sci Rep 2016;6:37287. PubMed
  12. Moon KA, Oberoi S, Barchowsky A, et al. A dose-response meta-analysis of chronic arsenic exposure and incident cardiovascular disease. Int J Epidemiol 2017;46(6):1924-39. PubMed
  13. Dong J, Su SY. The association between arsenic and children's intelligence: a meta-analysis. Biol Trace Elem Res 2009;129(1-3):88-93. PubMed
  14. Nong Q, Zhang Y, Guallar E, Zhong Q. Arsenic exposure and predicted 10-year atherosclerotic cardiovascular risk using the pooled cohort equations in U.S. hypertensive adults. Int J Environ Res Public Health 2016;13(11). pii: E1093. PubMed
  15. Sung TC, Huang JW, Guo HR. Association between arsenic exposure and diabetes: a meta-analysis. Biomed Res Int 2015;2015:368087. PubMed
  16. Tsinovoi CL, Xun P, McClure LA, et al. Arsenic exposure in relation to ischemic stroke: the reasons for geographic and racial differences in stroke study. Stroke 2018;49(1):19-26. PubMed
  17. Saint-Jacques N, Parker L, Brown P, Dummer TJ. Arsenic in drinking water and urinary tract cancers: a systematic review of 30 years of epidemiological evidence. Environ Health 2014;13:44. PubMed
  18. Quansah R, Armah FA, Essumang DK, et al. Association of arsenic with adverse pregnancy outcomes/infant mortality: a systematic review and meta-analysis. Environ Health Perspect 2015;123(5):412-21. PubMed
  19. Wang W, Xie Z, Lin Y, Zhang D. Association of inorganic arsenic exposure with type 2 diabetes mellitus: a meta-analysis. J Epidemiol Community Health 2014;68(2):176-84. PubMed
  20. Pichler G, Grau-Perez M, Tellez-Plaza M, et al. Association of arsenic exposure with cardiac geometry and left ventricular function in young adults. Circ Cardiovasc Imaging 2019;12(5):e009018. PubMed
  21. Rodríguez-Barranco M, Lacasaña M, Aguilar-Garduño C, et al. Association of arsenic, cadmium and manganese exposure with neurodevelopment and behavioural disorders in children: a systematic review and meta-analysis. Sci Total Environ 2013;454-455:562-77. PubMed
  22. Lu P, Ma JQ, Li F, et al. A fatal case of acute arsenic poisoning. J Forensic Sci 2019;64(4):1271-3. PubMed
  23. Dani SU. A curious association of chronic homeopathic arsenic ingestion with nonspecific symptoms in a Swiss teenager. Swiss Med Wkly 2019;149:w20071. PubMed
  24. Spilchuk V, Thompson A. Chronic arsenic poisoning from traditional Chinese medicine. CMAJ 2019;191(15):E424. PubMed
  25. Zhong Q, Cui Y, Wu H, et al. Association of maternal arsenic exposure with birth size: a systematic review and meta-analysis. Environ Toxicol Pharmacol 2019;69:129-36. PubMed
  26. Mullin AM, Amarasiriwardena C, Cantoral-Preciado A, et al. Maternal blood arsenic levels and associations with birth weight-for-gestational age. Environ Res 2019;177:108603. PubMed
  27. Wang B, Zhu Y, Yan L, et al. Association of maternal chronic arsenic exposure with the risk of neural tube defects in Northern China. Environ Int 2019;126:222-7. PubMed
  28. Chen Y, Wu F, Liu X, et al. Early life and adolescent arsenic exposure from drinking water and blood pressure in adolescence. Environ Res 2019;178:108681. PubMed
  29. Salmeri N, Villanacci R, Ottolina J, et al. Maternal Arsenic Exposure and Gestational Diabetes: A Systematic Review and Meta-Analysis. Nutrients 2020;12(10):3094. PubMed
  30. Di Giovanni P, Di Martino G, Scampoli P, et al. Arsenic Exposure and Risk of Urothelial Cancer: Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2020;17(9):3105. PubMed
  31. Liu R, Tabuchi T, Kitamura T, Miyashiro I, Sobue T. Long-term observational study on 6223 survivors of arsenic poisoning due to contaminated milk powder during infancy. Cancer Sci 2020;111(10):3873-3880. PubMed
  32. Zhao J, Li A, Mei Y, et al. The association of arsenic exposure with hypertension and blood pressure: A systematic review and dose-response meta-analysis. Environ Pollut 2021;289:117914. PubMed
  33. Yang Y, McDonald AC, Wang X, Pan Y, Wang M. Arsenic exposures and prostate cancer risk: A multilevel meta-analysis. J Trace Elem Med Biol 2022;72:126992. PubMed
  34. Kuo CC, Balakrishnan P, Gribble MO, et al. The association of arsenic exposure and arsenic metabolism with all-cause, cardiovascular and cancer mortality in the Strong Heart Study. Environ Int 2022;159:107029. PubMed
  35. Theruvath AH, Raveendran R, Philips CA. Dangerous placebo during the COVID-19 pandemic: A series of homoeopathic Arsenicum album-induced liver injury. Cureus 2022;14(6):e26062. PubMed

See these in context on the Arsenic monograph →

Calcium 62 references
  1. Shils M, Olson A, Shike M. Modern Nutrition in Health and Disease. 8th ed. Philadelphia, PA: Lea and Febiger, 1994.
  2. Hernandez-Avila M, Gonzalez-Cossio T, Hernandez-Avila JE, et al. Dietary calcium supplements to lower blood lead levels in lactating women: a randomized placebo-controlled trial. Epidemiology 2003;14:206-12.. PubMed
  3. Thys-Jacobs S, Ceccarelli S, Bierman A, et al. Calcium supplementation in premenstrual syndrome: a randomized crossover trial. J Gen Intern Med 1989;4:183-9. PubMed
  4. Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs 1999;57:855-70.
  5. Clemens JD, Feinstein AR. Calcium carbonate and constipation: a historical review of medical mythopoeia. Gastroenterology 1977;72:957-61. DOI
  6. Saunders D, Sillery J, Chapman R. Effect of calcium carbonate and aluminum hydroxide on human intestinal function. Dig Dis Sci 1988;33:409-13. PubMed
  7. Friedman PA, Bushinsky DA. Diuretic effects on calcium metabolism. Semin Nephrol 1999;19:551-6.
  8. Koo WK, Walters JC, Esterlitz J, et al. Maternal calcium supplementation and fetal bone mineralization. Obstet Gynecol 1999;94:577-82. DOI
  9. Raman L, Rajalakshmi K, Krishnamachari KAVR, et al. Effect of calcium supplementation to undernourished mothers during pregnancy on the bone density of the neonates. Am J Clin Nutr 1978; 31:466-9. DOI
  10. Murry JJ, Healy MD. Drug-mineral interactions: a new responsibility for the hospital dietician. J Am Diet Assoc 1991;91:66-73.
  11. Chan JM, Giovannucci E, Andersson SO, et al. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer. Cancer Causes Control 1998;9:559-66.
  12. Butner LE, Fulco PP, Feldman G, et al. Calcium carbonate-induced hypothyroidism. Ann Intern Med 2000:132:595. PubMed
  13. Schneyer CR. Calcium carbonate and reduction of levothyroxine efficacy. JAMA 1998;279:750. PubMed
  14. Moser LR, Smythe MA, Tisdale JE. The use of calcium salts in the prevention and management of verapamil-induced hypotension. Ann Pharmacother 2000;34:622-9. PubMed
  15. Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA 2000;283:2822-5. PubMed
  16. Kahela P, Anttila M, Tikkanen R, Sundquist H. Effect of food, food constituents and fluid volume on the bioavailability of sotalol. Acta Pharmacol Toxicol (Copenh) 1979;44:7-12.. PubMed
  17. Pletz MW, Petzold P, Allen A, et al. Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. Antimicrob Agents Chemother 2003;47:2158-60.. PubMed
  18. Bar-Or D, Yoel G. Calcium and calciferol antagonize effect of verapamil in atrial fibrillation. Br Med J 1981;282:1585-6.
  19. Decktor DL, Robinson M, Maton PN, et al. Effects of aluminum/magnesium hydroxide and calcium carbonate on esophageal and gastric pH in subjects with heartburn. Am J Ther 1995;2:546-52. PubMed
  20. Simoneau G. Absence of rebound effect with calcium carbonate. Eur J Drug Metab Pharmacokinet 1996;21:351-7. PubMed
  21. Peters ML, Leonard M, Licata AA. Role of alendronate and risedronate in preventing and treating osteoporosis. Cleve Clin J Med 2001;68:945-51. PubMed
  22. Bourke JF, Mumford R, Whittaker P, et al. The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis. J Am Acad Dermatol 1997;37:929-34.
  23. Gueguen L, Pointillart A. The bioavailability of dietary calcium. J Am Coll Nutr 2000;19:119s-136s. PubMed
  24. Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J 1999;75:554-6. PubMed
  25. Bania TC, Blaufeux B, Hughes S, et al. Calcium and digoxin vs. calcium alone for severe verapamil toxicity. Acad Emerg Med 2000;7:1089-96. PubMed
  26. Tseng M, Breslow RA, Graubard BI, Ziegler RG. Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am J Clin Nutr 2005;81:1147-54. PubMed
  27. Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev 2004;(1):CD003548. PubMed
  28. Tavani A, Bertuccio P, Bosetti C, et al. Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer. Eur Urol 2005;48:27-33. PubMed
  29. Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:203-10. PubMed
  30. Rocephin (ceftriaxone) and calcium interaction. Pharmacist's Letter / Prescriber's Letter 2007;23(10):231005.
  31. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised control trial. BMJ 2008;336:262-6.
  32. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691. PubMed
  33. Calcium supplementation and vascular events. Pharmacist's Letter / Prescriber's Letter 2008;24(3):240306.
  34. Dietary reference intakes for calcium and vitamin D. Institute of Medicine, November 30, 2010. Available at: http://www.iom.edu/~/media/Files/Report%20Files/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Vitamin%20D%20and%20Calcium%202010%20Repo
  35. Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis. 1991;17(6):708-11. PubMed
  36. Bradley JS, Wassel RT, Lee L, et al. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics. 2009;123(4):e609-13. PubMed
  37. Kays MB, Overholser BR, Mueller BA, et al. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis. 2003;42(6):1253-9. PubMed
  38. Neuhofel, A. L., Wilton, J. H., Victory, J. M., Hejmanowsk, L. G., and Amsden, G. W. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol. 2002;42(4):461-466. DOI
  39. Dickinson, H. O., Nicolson, D. J., Cook, J. V., Campbell, F., Beyer, F. R., Ford, G. A., and Mason, J. Calcium supplementation for the management of primary hypertension in adults. Cochrane.Database.Syst.Rev. 2006;(2):CD004639. PubMed
  40. Jones, B. J. and Twomey, P. J. Requesting patterns for serum calcium concentration in patients on long-term lithium therapy. Int J Clin Pract. 2009;63(1):170-172. PubMed
  41. Levine, M., Nikkanen, H., and Pallin, D. J. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg.Med. 2011;40(1):41-46. PubMed
  42. Castelo-Branco, C., Ciria-Recasens, M., Cancelo-Hidalgo, M. J., Palacios, S., Haya-Palazuelos, J., Carbonell-Abello, J., Blanch-Rubio, J., Martinez-Zapata, M. J., Manasanch, J., and Perez-Edo, L. Efficacy of ossein-hydroxyapatite complex compared with ca
  43. Li K, Kaaks R, Linseisen J, Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation i
  44. Chung M, Tang AM, Fu Z. Calcium Intake and Cardiovascular Disease Risk: An Updated Systematic Review and Meta-analysis. Ann Intern Med. 2016 Oct 25. PubMed
  45. Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int. 1990;38(5):937-41. PubMed
  46. Lewis JR, Radavelli-Bagatini S, Rejnmark L, et al. The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. J Bone Miner Res PubMed
  47. Jalloh MA, Gregory PJ, Hein D, et al. Dietary supplement interactions with antiretrovirals: a systematic review. Int J STD AIDS. 2017 Jan;28(1):4-15. PubMed
  48. Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, Baggerly K, McDonnell SL. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. JAMA. 2017 Mar 28;317(12):1234-1243. PubMed
  49. Grove ML, Cook D. Calcium and heart attacks. Doesn't apply to most calcium prescriptions. BMJ. 2010;341:c5003. PubMed
  50. Insentress [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2014.
  51. Roberts JL, Kiser JJ, Hindman JT, Meditz AL. Virologic failure with a raltegravir-containing antiretroviral regimen and concomitant calcium administration. Pharmacotherapy 2011;31(10):298e-302e. DOI
  52. Vitekta [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2014.
  53. Storan ER, O'Gorman SM, Murphy A, Laing M. Case Report of Calciphylaxis Secondary to Calcium and Vitamin D<sub>3</sub> Supplementation. J Cutan Med Surg. 2017;21(2):162-163. DOI
  54. Jenkins DJA, Spence JD, Giovannucci EL, et al. Supplemental vitamins and minerals for CVD prevention and treatment. J Am Coll Cardiol 2018;71(22):2570-84. PubMed
  55. Borkenhagen JF, Connor EL, Stafstrom CE. Neonatal hypocalcemic seizures due to excessive maternal calcium ingestion. Pediatr Neurol 2013;48(6):469-71. PubMed
  56. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: World Health Organization; 2016 (http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/ anc-positive-pregnancy-experience/en/).
  57. Aune D, Navarro Rosenblatt DA, Chan DS, et al. Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies. Am J Clin Nutr. 2015;101(1):87-117. PubMed
  58. Lan T, Park Y, Colditz GA, et al. Adolescent dairy product and calcium intake in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study. Cancer Causes Control. 2020;31(10):891-904. PubMed
  59. Zhang Y, Li Y, Liu J, et al. Association of Vitamin D or Calcium Supplementation with Cardiovascular Outcomes and Mortality: A Meta-Analysis with Trial Sequential Analysis. J Nutr Health Aging 2021;25(2):263-270. PubMed
  60. Myung SK, Kim HB, Lee YJ, Choi YJ, Oh SW. Calcium Supplements and Risk of Cardiovascular Disease: A Meta-Analysis of Clinical Trials. Nutrients 2021;13(2):368. PubMed
  61. Hetaimish B. Neonatal Calcinosis Cutis After Treatment of Hypocalcemia with Calcium Gluconate: A Report of 2 Cases. Am J Case Rep 2024;25:e943397. PubMed
  62. US Food and Drug Administration (FDA). Biktarvy Prescribing Information. October 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210251Orig1s020lbl.pdf. Accessed July 16, 2025.

See these in context on the Calcium monograph →

Activated Charcoal 14 references
  1. Kaaja RJ, Kontula KK, Raiha A, Laatikainen T. Treatment of cholestasis of pregnancy with peroral activated charcoal. A preliminary study. Scand J Gastroenterol 1994;29:178-81.
  2. Anon. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin T
  3. Park GD, Spector R, Kitt TM. Superactivated charcoal versus cholestyramine for cholesterol lowering: a randomized cross-over trial. J Clin Pharmacol 1988;28:416-9. PubMed
  4. Hoegberg LC, Angelo HR, Christophersen AB, Christensen HR. Effect of ethanol and pH on the adsorption of acetaminophen (paracetamol) to high surface activated charcoal, in vitro studies. J Toxicol Clin Toxicol 2002;40:59-67. PubMed
  5. Brahmi N, Kouraichi N, Thabet H, Amamou M. Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. Am J Emerg Med 2006;24(4):440-3. PubMed
  6. Gude AB, Hoegberg LC, Angelo HR, Christensen HR. Dose-dependent adsorptive capacity of activated charcoal for gastrointestinal decontamination of a simulated paracetamol overdose in human volunteers. Basic Clin Pharmacol Toxicol 2010;106(5)406-10. PubMed
  7. Wananukul W, Klaikleun S, Sriapha C, Tongpoo A. Effect of activated charcoal in reducing paracetamol absorption at supra-therapeutic dose. J Med Assoc Thai 2010;93(10):1145-9.
  8. Wang Z, Cui M, Tang L, et al. Oral activated charcoal suppresses hyperphosphataemia in haemodialysis patients. Nephrology (Carlton) 2012;17(7):616-20. PubMed
  9. Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014;14(2):147-54. PubMed
  10. Chyka PA, Seger D, Krenzelok EP, et al. Position paper: single-dose activated charcoal. Clin Toxicol (Phila) 2005;43(2):61-87. PubMed
  11. Chiew AL, Gluud C, Brok J, Buckley NA. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2018;2:CD003328. PubMed
  12. Elomaa K, Ranta S, Tuominen J, L&auml;hteenm&auml;ki P. Charcoal treatment and risk of escape ovulation in oral contraceptive users. Hum Reprod. 2001;16(1):76-81. PubMed
  13. Gao Y, Wang G, Li Y, Lv C, Wang Z. Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease. J Nephrol. 2019;32(2):265-72. PubMed
  14. Skov K, Graudal NA, Jürgens G. The effect of activated charcoal on drug exposure following intravenous administration: A meta-analysis. Basic Clin Pharmacol Toxicol 2021;128(4):568-578. PubMed

See these in context on the Activated Charcoal monograph →

Cinchona 15 references
  1. The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
  2. Wichtl MW. Herbal Drugs and Phytopharmaceuticals. Ed. N.M. Bisset. Stuttgart: Medpharm GmbH Scientific Publishers, 1994.
  3. Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics. 2nd ed. New York, NY: John Wiley & Sons, 1996.
  4. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
  5. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
  6. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
  7. Holt GA. Food & Possible Interactions with Drugs: Revised and Expanded Ed. Chicago, IL: Precept Press, 1998.
  8. Hardman JG, Limbird LL, Molinoff PB, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996.
  9. Hansten PD, Horn JR. Drug Interactions Analysis and Management. Vancouver, WA: Applied Therapeutics Inc., 1997 and updates.
  10. Amabeoku GJ, Chikuni O, Akino C, Mutetwa S. Pharmacokinetic interaction of single doses of quinine and carbamazepine, phenobarbitone and phenytoin in healthy volunteers. East Afr Med J 1993;70:90-3.
  11. Shah BH, Nawaz Z, Virani SS, Ali IQ, Saeed SA, Gilani AH.The inhibitory effect of cinchonine on human platelet aggregation due to blockade of calcium influx. Biochem Pharmacol 1998;56:955-60. PubMed
  12. US Food and Drug Administration notice: Drug products containing quinine - enforcement action dates. Docket # 2006N-0476. Federal Register 2006 (December 15);71 (241): 75557-60.
  13. FDA Drug Safety Communication: New risk management plan and patient medication guide for Qualaquin (quinine sulfate). 07-08-2010. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218202 (accessed 02/18/17).
  14. Dooms-Goossens A, Deveylder H, Duron C, et al. Airborne contact urticaria due to cinchona. Contact Dermatitis 1986;15(4):258. PubMed
  15. Bramer SL, Suri A. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:41-51. PubMed

See these in context on the Cinchona monograph →

Nux Vomica 7 references
  1. Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.
  2. Robbers JE, Speedie MK, Tyler VE. Pharmacognosy and Pharmacobiotechnology. Baltimore, MD: Williams & Wilkins, 1996.
  3. Ellenhorn MJ, et al. Ellenhorn's Medical Toxicology: Diagnoses and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams & Wilkins, 1997.
  4. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
  5. Hardman JG, Limbird LL, Molinoff PB, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996.
  6. Katz, J., Prescott, K., and Woolf, A. D. Strychnine poisoning from a Cambodian traditional remedy. Am J Emerg.Med 1996;14(5):475-477. PubMed
  7. Dai TY, Chen CC, Hong LL, et al. Effect evaluation of strychnos nux-vomica L. with integrative methods for bortezomib-induced peripheral neuropathy in multiple myeloma patients: A self-controlled clinical trial. Chin J Integr Med. 2020 May 16. PubMed

See these in context on the Nux Vomica monograph →

Star Of Bethlehem 8 references
  1. Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.
  2. Ellenhorn MJ, et al. Ellenhorn's Medical Toxicology: Diagnoses and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams & Wilkins, 1997.
  3. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
  4. Burnham TH, ed. Drug Facts and Comparisons, Updated Monthly. Facts and Comparisons, St. Louis, MO.
  5. Waud RA. The action of Ornithogalum umbellatum on the heart. J Pharmacol Exp Ther 1954;111:147-51. DOI
  6. Vogelsang A. Ornithogalum umbellatum in the treatment of congestive heart failure: progress report. J Am Geriatr Soc 1961;9:1096-9.
  7. Vogelsang A. Clinical trial of Ornithogalum umbellatum on the human heart; preliminary report. Can Med Assoc J 1955;73:295-6.
  8. Smith JA, Paterson GR. Rhodexin A and rhodexoside in Ornithogalum umbellatum. J Pharm Pharmacol 1967;19:221-5.

See these in context on the Star Of Bethlehem monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring
Supplement interaction checker › Check any supplement or product against your medications Drug–drug interactions › Check two or more of your medications against each other Browse medications A–Z › Every drug we've checked against herbs & supplements NDC & pricing lookup › Find a drug’s NDCs, packaging and costs Ask a pharmacist › Free, personal answer from our licensed team